| Identification | Back Directory | [Name]
Gemcitabine monophosphate | [CAS]
1638288-31-9 | [Synonyms]
GemMP
Gemcitabine monophosphate disodium
Gemcitabine monophosphate disodium salt
GEMCITABINE MONOPHOSPHATE DISODIUM SALT MONOHYDRATE; GEMCITABINE MONOPHOSPHATE DISODIUM; GEMMP | [Molecular Formula]
C9H13F2N3NaO7P | [MDL Number]
MFCD18252926 | [MOL File]
1638288-31-9.mol | [Molecular Weight]
367.18 |
| Hazard Information | Back Directory | [Uses]
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles[1][2]. | [in vivo]
Gemcitabine monophosphate (19.5 mg/kg, intravenous injection, every other day, four injections) combined with LCP loaded with VEGF siRNA and GMP shows anti-small cell lung cancer activity and induces apoptosis[1]. | Animal Model: | Subcutaneous and orthotopic xenograft mouse models of non-small cell lung cancer[1] | | Dosage: | 19.5 mg/kg, every other day, four injections | | Administration: | Intravenous injection (i.v.) | | Result: | Induced tumor cell apoptosis to 30-40%, reduced tumor cell proliferation by 8 times, significantly reduced tumor microvessel density (MVD), and inhibited tumor mitosis. |
| [References]
[1] Zhang Y, et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther. 2013 Aug;21(8):1559-69. DOI:10.1038/mt.2013.120
[2] Miao L, et al. Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct Mater. 2014 Nov 12;24(42):6601-6611. DOI:10.1002/adfm.201401076 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|